Inovio Pharmaceuticals announced today that it will begin human testing on a DNA-based vaccine for the Zika virus.
Testing for the experimental vaccine will start in the coming weeks, in a partnership with GeneOne Life Science.
The 40-person study will use genetically engineered materials that mimic the Zika virus. This study follows Inovio’s earlier tests with animals, which responded well to the vaccine.
Patt Morrison discusses the logistics of this trial period with professor of preventative medicine, William Schaffner, and what the public can expect, should the vaccine become available.
With files from the Associated Press.
William Schaffner, MD, Professor of Preventive Medicine at the Vanderbilt University Medical Center in Nashville, TN